MAPT and Alzheimer disease: Trimethylamine N-oxide (TMAO), a metabolite derived from gut microbiota, has been shown to correlate with tau pathology, with increased TMAO concentrations observed in the cerebrospinal fluid (CSF) of AD patients, and a positive relationship with NFTs (Vogt et al., 2018).